ALN-TTR02: Extension study started

Alnylam began an open-label extension trial to evaluate 0.3 mg/kg IV ALN-TTR02 every 3 weeks for up to 2 years in patients who completed an open-label, dose-escalation, international Phase II trial evaluating 0.01-0.3 mg/kg IV ALN-TTR02 every 3 or 4 weeks for 2 cycles. Initial data from the extension study are expected to be presented next year, with yearly updates afterwards. By year end, Alnylam plans to start a Phase III trial with ALN-TTR02 to treat familial amyloidotic polyneuropathy (FAP), a predominant clinical manifestation of TTR-mediated amyloidosis. ...